US3856469A - Interferant removal from amphetamine immunoassay - Google Patents

Interferant removal from amphetamine immunoassay Download PDF

Info

Publication number
US3856469A
US3856469A US00320374A US32037473A US3856469A US 3856469 A US3856469 A US 3856469A US 00320374 A US00320374 A US 00320374A US 32037473 A US32037473 A US 32037473A US 3856469 A US3856469 A US 3856469A
Authority
US
United States
Prior art keywords
periodate
ammonium hydroxide
amphetamine
range
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00320374A
Inventor
R Schneider
E Ullman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYVA CORP
SYVA CORP US
Original Assignee
SYVA CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYVA CORP filed Critical SYVA CORP
Priority to US00320374A priority Critical patent/US3856469A/en
Application granted granted Critical
Publication of US3856469A publication Critical patent/US3856469A/en
Anticipated expiration legal-status Critical
Assigned to DEUTSCHE BANK AG reassignment DEUTSCHE BANK AG SECURITY AGREEMENT Assignors: DADE MICROSCAN INC.
Assigned to DEUTSCHE BANK AG reassignment DEUTSCHE BANK AG SEE RECORDING AT REEL 013599 FRAME 0629. DOCUMENT RECORDED OVER TO ADD OMITTED PAGE OF THE SCHEDULE. Assignors: DADE MICROSCAN INC.
Assigned to DEUTSCHE BANK AG reassignment DEUTSCHE BANK AG SECURITY AGREEMENT Assignors: SYVA COMPANY
Assigned to SYVA COMPANY reassignment SYVA COMPANY RELEASE OF SECURITY INTEREST Assignors: DEUTSCHE BANK AG, NEW YORK BRANCH
Assigned to DADE MICROSCAN INC. reassignment DADE MICROSCAN INC. RELEASE OF SECURITY INTEREST Assignors: DEUTSCHE BANK AG, NEW YORK BRANCH
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/803—Stabe free radicals, e.g. spin immunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives

Definitions

  • Field of the Invention There is frequent need for accurate and reliable determination of amphetamine, methamphetamine or like materials. Since amphetamine is a drug of abuse, there is the police function of determining whether a person has taken amphetamine. There is also the medicinal function of determining the amount of amphetamine in a biological fluid.
  • Phenylpropanolamine is a common drug sold over the counter, which is taken in relatively large dosages. Because of the relatively high concentration of the phenylpropanolamine in biological fluids when used and the structural similarity of the phenylpropanolamine to amphetamine, the phenylpropanolamine obscures the detection of the amphetamine, for example, in chromatography or by providing a false signal, as in immunoassays.
  • lmmunoassays are based on employing a receptor, usually an antibody, which is capable of recognizing or distinguishing a particular chemical structure. By employing techniques which distinguish between those compounds which bind to the receptor and those compounds which do not, the compound recognized by the receptor can be determined, qualitatively or quantitatively.
  • Radioimmunoassays which allow for a competition between a radioactively labelled compound and the compound to be assayed have been known for a long time. More recently, two new and unique methods have been developed. The first method employs an electron spin resonance technique, entitled FRAT, supplied by Syva Corp. The second technique employs enzyme labelled with a compound which simulates the compound to be assayed, and is called EMIT also supplied by Syva Corp. The accuracy of these techniques is dependent upon, among other variables, the ability for the receptor the antibody to recognize a specific compound. In preparing antibodies to a specific compound, the compound is bonded to an antigen and the antigen injected in an animal. This results in the production of antibodies which recognize the compound. Compounds which have this property are referred to as haptens.
  • antibodies While antibodies show high specificity for particular geometry or spatial configuration and a particular distribution of polar and non-polar groups, antibodies will frequently recognize similar compounds to a lesser degree and infrequently to a greater degree. This recognition of compounds other than the compound of interest is referred to as cross-reactivity.
  • B-phenethyl amine e.g., amphetamine and methamphetamine
  • B-hydroxyphenethyl amine compounds are antibody to distinguish between the two must not interfere with the assay system.
  • it must not affect the phenethylamine derivative, so as to modify the response of the antibody to the phenethylamine derivative.
  • the method chosen affect the label, so as to give a spurious result.
  • a medium to be assayed for a phenethylamine derivative is combined with a small amount of an aqueous periodate solution at a mild temperature and mildly basic pH for a sufficient time to modify any B-hydroxy- B-phenethylamine derivative, which acts as an interferant, so as to destroy its interfering effect.
  • the sample is then used in the determination without interference from the B-hydroxyamine.
  • the method finds particular use with immunoassays.
  • Liquid media suspected of containing a B-phenethylamine derivative, such as amphetamine or methamphetamine are treated with a small amount of periodate at a mildly basic pH 8) for a sufficient time to modify any aralkyl ,8phenethylamines, so as to prevent obtaining a spurious result because of the presence of phenylpropanolamine or the like compound. That is, those compounds having vicinal hydroxyamines and an aliphatic group bonded to a phenyl ring. These interferants are normally of from eight to 10 carbon atoms.
  • the sample may then be used in a normal way in any of the variety of determinations, such as thin layer chromatography, immunoassays, e.g., radioimmunoassay, the electron spin resonance technique, referred to as FRAT or the enzyme technique, referred to as EMIT
  • immunoassays will usually be carried out at a pH below 8, usually in the range of 5.0 to 7.5, more usually 5.5 to 7.0.
  • the medium may be any source suspected of containing the phenethylamine. Of particular interest are physiological media, such as blood serum, saliva, and urine, particularly urine. Any of the normal treatments given to the fluid may be carried out prior to the periodate treatment. When the medium has been properly prepared, it is combined with the periodate at a mildly basic pH and allowed to stand, with mild agitation if desired, for a sufficient time to modify or destroy the interfering substances sensitive to the periodate treatment.
  • the amount of periodate will vary depending on the particular medium and the suspected degree of contamination with interferants, but will normally be in the range of about 10" to 10 moles/ml, and more usually about 10 to 10 moles/ml, and particularly about
  • the basic pH usually in the range of 8 to 10
  • the periodate forms complex ions with varying pH and these complex ions are of varying solubility in aqueous systems.
  • ammonium hydroxide (ammonium includes quaternary ammonium hydroxides of from 1 to 12, usually one to six carbon atoms) is used to achieve the desired pH.
  • Preferred hydroxides are ammonium hydroxide (NH OH) and tetraalkyl ammonium hydroxide of from four to eight carbon atoms.
  • the ammonium hydroxide will be present in amounts sufficient to provide a pH of the treated medium in the range of about 8 to 10 usually 8 to 9.
  • the amount in moles of ammonium hydroxide will be 2 to 20 times that of moles of periodate, more usually from about 5 to times that of the periodate.
  • a reagent solution can be prepared which is 0.01 to 0.5, more usually 0.05 to 0.3 M in periodate and 0.25 to 2, more usually 0.5 to 1.5 M in ammonium hydroxide.
  • the temperature of the periodate treatment will normally be in the range of about 0 to 40C, more usually from about 10 to 30C, and the assays can be conveniently carried out at ambient temperatures.
  • the time for treatment will usually be as short as possible to obtain the desired results and will usually be from about 1 to 10 minutes, more usually about 5 minutes.
  • the periodate is conveniently employed as an alkali metal periodate, particularly sodium and potassium, and preferably sodium.
  • the quaternary ammonium hydroxides are illustrated by tetraethylammonium hydroxide, diethyldimethylammonium hydroxide, N,N- dimethyl piperidinium hydroxide, N-methyl pyridinium hydroxide, and the like. Usually, the quaternary ammonium hydroxide will be free of unsaturation, both aliphatic and aromatic.
  • the sample After treatment with the periodate, the sample is ready to be used.
  • the assay solution is normally sufficiently buffered to control the pH.
  • the immunoassay solution will normally be at a pH of 7.5 or below. At these pHs, the periodate is found not to adversely affect the various reagents or interfere with the immunoassay determination.
  • the sample may be used directly.
  • N-carboxymethylamphetamine was employed for determining the amphetamine present.
  • N-carboxymethylamphetamine was conjugated with lysozyme as follows:
  • N-carboxymethylamphetamine mg, 0.133mM was suspended in 1.8 ml of dry dioxane at 40.
  • Phosgene 12.5 volume percent in benzene) (0.715 ml) was added in one portion.
  • the reaction mixture was stirred at 40 for 3.5 hours before an additional 0.2 ml of phosgene (12.5 volume percent in benzene) was added. After stirring an additional 30 minutes, the solution became homogeneous.
  • the solvent was removed in vacuo at 25 in the hood. An additional 0.70 ml of dry dioxane was added for use in the next step.
  • the cold dioxane solution of the above product was added dropwise over 5 minutes to a stirred, cold (0) solution of 200 mg sodium bicarbonate and 100 mg lysozyme in 10 ml water.
  • the milky reaction mixture was stirred at 4 for 48 hours and dialyzed against 1.1 changed 3 times daily over a 48 hour period. The residue was lyophilized.
  • the assay is carried out by combining 0.2 ml of M. luteus (30 mg) in 50 ml of 0.05 M Tris-maleate of pH 6 and 20A of amphetamine antibody (1.3 X 10""M in binding sites), followed by the addition of A of the urine sample.
  • the mixture was then diluted with 0.5 ml of a solution of the above modified enzyme to provide a ratio of binding sites to moles of lysozyme of 1.5: 1.
  • the reaction mixture was then aspirated into the spectrometer and the decrease in optical density measured at 436 nm for 40 seconds at 30.
  • the periodate is very effective in removing phenylpropanolamine and ephedrine as an interferant. While the result for amphetamine changes with periodate treatment, a different standard curve can be obtained, which is reproducible, so that the same results for the amphetamine can be obtained with and without periodate treatment by using a different standard curve, where an interferant is not present.
  • Samples of lyophylized urine containing 0.0 and 1.0 ,ug/ml of amphetamine were employed. Employing the assay technique described above, the 0.0 sample gave readings of 48; 50; 50 OD/min, and the 1.0 ag/ml sample gave readings of 59; 61 OD/min.
  • 200 a! of aqueous sample was combined with 10 ,ul of 0.5 g/ml sodium periodate and 10 pl ammonium hydroxide (10 wt percent in water) the results for the two samples were: 0.0 ,ug/ml-48; 50; and 1.0 ug/ml-62', 57.
  • the improvement which comprises: treating the sample to be assayed at a pH greater than about 8 with an amount of aqueous periodate solution sufficient to remove the with 100 [1.] aqueous phenylpropanolamine solution 5 hydroxyamine interferant wherein said pH is main- (55 ,ug/ml) the readings were 41; 46 OD/min. This is tained by the presence of an ammonium hydroxide. equivalent to background.
  • a method for carrying out immunoassays to decentration of borate buffer at pH 8.0 is 0.18 M.
  • the tect amphetamine or methamphetamine, the improvesample is treated with a small amount of dichromate to 20 ment which comprises: treating the sample to be asdestroy any ascorbic acid and 20 pl of sample is added sayed with aqueous periodate solution at a concentrato 5 ,ul of antibody solution and 5 ul of the spin label tion in the range of about 10 to 10 moles/ml in the at the appropriate buffer concentration.
  • the sample is presence f a a niu h droxide in an amount sufthen taken up in an ESR capillary tube and read in an fici nt to provide a pH in the range of about 8 to 9.
  • monium hydroxide is tetramethyl ammonium hydrox- The following table indicates the results. ide,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method for removing Beta -hydroxyamine compounds as an interferant from immunoassays, where like compounds, such as amphetamine, methamphetamine, and the like are to be determined. The sample, for example, urine is treated with aqueous periodate at a mildly basic pH for a time sufficient to remove the Beta hydroxyamine as an interferant, the pH being maintained by an ammonium hydroxide. The sample may then be used in assays for the determination of amphetamine or like compounds without interference from the Beta -hydroxyamine compound.

Description

nited States Patent [191 Schneider et al.
[ INTERFERANT REMOVAL FROM AMPHETAMINE IMMUNOASSAY [75] Inventors: Richard S. Schneider, Sunnyvale;
Edwin F. Ullman, Atherton, both of Calif.
[73] Assignee: Syva Corporation, Palo Alto, Calif.
[22] Filed: Jan. 2, 1973 [21] Appl. N0.: 320,374 7 [52] U.S. Cl. 23/230 B, 250/303, 252/187 R,
260/5708 R, 424/12 [51] Int. Cl.. G01n 23/00, G01n 31/02, GOln 33/16 [58] Field of Search 23/230 B; 252/186, 187 R;
424/12 [56] References Cited UNITED STATES PATENTS 3,766,162 10/1973 Spector 424/12 X OTHER PUBLICATIONS L. Chafetz, J. Pharm. Sci., 52, (12), 11931195, (1963). Chemical Abstracts, 63: 8942f, (1965).
[ Dec. 24, 1974 Primary ExaminerMorris O. Wolk Assistant ExaminerSidney Marantz [57] ABSTRACT 10 Claims, N0 Drawings INTERFERANT REMOVAL FROM AMPHETAMINE IMMUNOASSAY BACKGROUND OF THE INVENTION 1. Field of the Invention There is frequent need for accurate and reliable determination of amphetamine, methamphetamine or like materials. Since amphetamine is a drug of abuse, there is the police function of determining whether a person has taken amphetamine. There is also the medicinal function of determining the amount of amphetamine in a biological fluid.
Phenylpropanolamine is a common drug sold over the counter, which is taken in relatively large dosages. Because of the relatively high concentration of the phenylpropanolamine in biological fluids when used and the structural similarity of the phenylpropanolamine to amphetamine, the phenylpropanolamine obscures the detection of the amphetamine, for example, in chromatography or by providing a false signal, as in immunoassays.
lmmunoassays are based on employing a receptor, usually an antibody, which is capable of recognizing or distinguishing a particular chemical structure. By employing techniques which distinguish between those compounds which bind to the receptor and those compounds which do not, the compound recognized by the receptor can be determined, qualitatively or quantitatively.
Radioimmunoassays which allow for a competition between a radioactively labelled compound and the compound to be assayed have been known for a long time. More recently, two new and unique methods have been developed. The first method employs an electron spin resonance technique, entitled FRAT, supplied by Syva Corp. The second technique employs enzyme labelled with a compound which simulates the compound to be assayed, and is called EMIT also supplied by Syva Corp. The accuracy of these techniques is dependent upon, among other variables, the ability for the receptor the antibody to recognize a specific compound. In preparing antibodies to a specific compound, the compound is bonded to an antigen and the antigen injected in an animal. This results in the production of antibodies which recognize the compound. Compounds which have this property are referred to as haptens.
While antibodies show high specificity for particular geometry or spatial configuration and a particular distribution of polar and non-polar groups, antibodies will frequently recognize similar compounds to a lesser degree and infrequently to a greater degree. This recognition of compounds other than the compound of interest is referred to as cross-reactivity.
Where there is undesirable cross-reactivity, and the cross-reacting compound is sufficiently prevalent in the samples to be determined, so as to be of concern, it is necessary to find some way to remove or change the compound, so that the antibody will not recognize it or bind the compound. It is found that with derivatives of B-phenethyl amine, e.g., amphetamine and methamphetamine, B-hydroxyphenethyl amine compounds are antibody to distinguish between the two must not interfere with the assay system. Furthermore, it must not affect the phenethylamine derivative, so as to modify the response of the antibody to the phenethylamine derivative. Nor may the method chosen affect the label, so as to give a spurious result.
2. Description of the Prior Art A description of the free radical assay technique can be found in US. Pat. No. 3,690,834, issued Sept. 12, 1972. A description of the enzyme technique may be found in copending application Ser. No. 143,609, filed May 14, 1971, now abandoned. A description of the radioimmunoassay technique may be found in numerous texts, such as Kirkham, et al., Radioimmunoassay Methods, European Workshop, September 1970, Churchill, London 1971; Ferrari, Gazz. Chim. Ital. 92 22 (1962) reports the formation of crystalline tetramethylammonium periodate.
SUMMARY OF THE INVENTION A medium to be assayed for a phenethylamine derivative is combined with a small amount of an aqueous periodate solution at a mild temperature and mildly basic pH for a sufficient time to modify any B-hydroxy- B-phenethylamine derivative, which acts as an interferant, so as to destroy its interfering effect. The sample is then used in the determination without interference from the B-hydroxyamine. The method finds particular use with immunoassays.
DESCRIPTION OF THE PREFERRED EMBODIMENTS Liquid media suspected of containing a B-phenethylamine derivative, such as amphetamine or methamphetamine are treated with a small amount of periodate at a mildly basic pH 8) for a sufficient time to modify any aralkyl ,8phenethylamines, so as to prevent obtaining a spurious result because of the presence of phenylpropanolamine or the like compound. That is, those compounds having vicinal hydroxyamines and an aliphatic group bonded to a phenyl ring. These interferants are normally of from eight to 10 carbon atoms.
The sample may then be used in a normal way in any of the variety of determinations, such as thin layer chromatography, immunoassays, e.g., radioimmunoassay, the electron spin resonance technique, referred to as FRAT or the enzyme technique, referred to as EMIT The immunoassays will usually be carried out at a pH below 8, usually in the range of 5.0 to 7.5, more usually 5.5 to 7.0.
The medium may be any source suspected of containing the phenethylamine. Of particular interest are physiological media, such as blood serum, saliva, and urine, particularly urine. Any of the normal treatments given to the fluid may be carried out prior to the periodate treatment. When the medium has been properly prepared, it is combined with the periodate at a mildly basic pH and allowed to stand, with mild agitation if desired, for a sufficient time to modify or destroy the interfering substances sensitive to the periodate treatment.
The amount of periodate will vary depending on the particular medium and the suspected degree of contamination with interferants, but will normally be in the range of about 10" to 10 moles/ml, and more usually about 10 to 10 moles/ml, and particularly about The basic pH, usually in the range of 8 to 10, can be achieved with a variety of bases. The periodate forms complex ions with varying pH and these complex ions are of varying solubility in aqueous systems. Conveniently, ammonium hydroxide (ammonium includes quaternary ammonium hydroxides of from 1 to 12, usually one to six carbon atoms) is used to achieve the desired pH. Preferred hydroxides are ammonium hydroxide (NH OH) and tetraalkyl ammonium hydroxide of from four to eight carbon atoms. The ammonium hydroxide will be present in amounts sufficient to provide a pH of the treated medium in the range of about 8 to 10 usually 8 to 9. Usually the amount in moles of ammonium hydroxide will be 2 to 20 times that of moles of periodate, more usually from about 5 to times that of the periodate. Conveniently, a reagent solution can be prepared which is 0.01 to 0.5, more usually 0.05 to 0.3 M in periodate and 0.25 to 2, more usually 0.5 to 1.5 M in ammonium hydroxide.
It is found that at concentrations of periodate useful as reagents for combining with physiological fluids, short shelf lives are obtained with the usual alkali metal cations at the basic pH. With tetraalkylammonium cations, long shelf lives are obtained, so that the reagents can be prepared, stored and shipped without any precipitate forming.
The temperature of the periodate treatment will normally be in the range of about 0 to 40C, more usually from about 10 to 30C, and the assays can be conveniently carried out at ambient temperatures. The time for treatment will usually be as short as possible to obtain the desired results and will usually be from about 1 to 10 minutes, more usually about 5 minutes.
The periodate is conveniently employed as an alkali metal periodate, particularly sodium and potassium, and preferably sodium. The quaternary ammonium hydroxides are illustrated by tetraethylammonium hydroxide, diethyldimethylammonium hydroxide, N,N- dimethyl piperidinium hydroxide, N-methyl pyridinium hydroxide, and the like. Usually, the quaternary ammonium hydroxide will be free of unsaturation, both aliphatic and aromatic.
After treatment with the periodate, the sample is ready to be used. In immunoassays, the assay solution is normally sufficiently buffered to control the pH. The immunoassay solution will normally be at a pH of 7.5 or below. At these pHs, the periodate is found not to adversely affect the various reagents or interfere with the immunoassay determination.
In other types of determination, e.g., chromatography thin layer chromatography the sample may be used directly.
To demonstrate the subject invention, a number of urine samples were tested, employing the enzyme assay system. In carrying out the test, ul ofa reagent which was 0.13 M in sodium periodate and 1.2 F in tetramethylammonium hydroxide was combined with urine 100 a1) and allowed to stand for five minutes.
In carrying out the assay, N-carboxymethylamphetamine was employed for determining the amphetamine present. N-carboxymethylamphetamine was conjugated with lysozyme as follows:
(All temperatures are in Centigrade) N-carboxymethylamphetamine mg, 0.133mM) was suspended in 1.8 ml of dry dioxane at 40. Phosgene 12.5 volume percent in benzene) (0.715 ml) was added in one portion. The reaction mixture was stirred at 40 for 3.5 hours before an additional 0.2 ml of phosgene (12.5 volume percent in benzene) was added. After stirring an additional 30 minutes, the solution became homogeneous. The solvent was removed in vacuo at 25 in the hood. An additional 0.70 ml of dry dioxane was added for use in the next step.
The cold dioxane solution of the above product was added dropwise over 5 minutes to a stirred, cold (0) solution of 200 mg sodium bicarbonate and 100 mg lysozyme in 10 ml water. The milky reaction mixture was stirred at 4 for 48 hours and dialyzed against 1.1 changed 3 times daily over a 48 hour period. The residue was lyophilized.
The assay is carried out by combining 0.2 ml of M. luteus (30 mg) in 50 ml of 0.05 M Tris-maleate of pH 6 and 20A of amphetamine antibody (1.3 X 10""M in binding sites), followed by the addition of A of the urine sample. The mixture was then diluted with 0.5 ml of a solution of the above modified enzyme to provide a ratio of binding sites to moles of lysozyme of 1.5: 1. The reaction mixture was then aspirated into the spectrometer and the decrease in optical density measured at 436 nm for 40 seconds at 30.
A standard urine sample was employed to which a va riety of different materials were added, and the results determined with and without the periodate treatment. The following table indicates the results:
The periodate is very effective in removing phenylpropanolamine and ephedrine as an interferant. While the result for amphetamine changes with periodate treatment, a different standard curve can be obtained, which is reproducible, so that the same results for the amphetamine can be obtained with and without periodate treatment by using a different standard curve, where an interferant is not present.
Samples of lyophylized urine containing 0.0 and 1.0 ,ug/ml of amphetamine were employed. Employing the assay technique described above, the 0.0 sample gave readings of 48; 50; 50 OD/min, and the 1.0 ag/ml sample gave readings of 59; 61 OD/min. When 200 a! of aqueous sample was combined with 10 ,ul of 0.5 g/ml sodium periodate and 10 pl ammonium hydroxide (10 wt percent in water) the results for the two samples were: 0.0 ,ug/ml-48; 50; and 1.0 ug/ml-62', 57. When aqueous phenylpropanolamine at a concentration of 55 pig/ml was employed the reading was 70; 81 OD/min. After treatment of the sample with the ammonium hydroxide and periodate and waiting five minutes, the readings were 52; 52 OD/min.
The further demonstrate the effect of the sodium periodate, u! of the 1.0 ug/ml amphetamine solution was combined with 15 pl of 0.5 g/10 ml aqueous sodium periodate and 5 pl of wt percent aqueous sodium hydroxide. The reading was 60 OD/min after 2 minutes. When the determination was repeated replacing the 100 .41 of 1.0 ,ug aqueous amphetamine solution wherein l-aralkyl ,B-hydroxyamines interfere, the improvement which comprises: treating the sample to be assayed at a pH greater than about 8 with an amount of aqueous periodate solution sufficient to remove the with 100 [1.] aqueous phenylpropanolamine solution 5 hydroxyamine interferant wherein said pH is main- (55 ,ug/ml) the readings were 41; 46 OD/min. This is tained by the presence of an ammonium hydroxide. equivalent to background. I 2. A method according to claim 1, wherein the con- A series of urine samples were obtained which were Y3T3:igfi igig fig' is m the range of about Li 2 g ifig gg g j g i j gF f' 0 3. A method according to claim 1, wherein said perig p p r en es e .accor mg 0 odate is at a concentration in the range of about 10 the above procedure by the enzyme techniques, as well to moles/ml as by the electron Spm resonance technique 4. A method according to claim 1, wherein the conln the FRAT assay, N'-2',2',5,5-tetramethylpyrcentration of said ammonium hydroxide is in an rolidinyl-l -oxyl 1-phenyl-2-propylaminoacetamide is amount of from 2 to times the concentration of perithe spin label reagent and is employed at a concentraodate and said ammonium hydroxide is tetraalkyl amtion of 2.85 X 10 M, with the mole ratio of spin label monium hydroxide. to a t dy (based on d g es) O 5 h 60 5. in a method for carrying out immunoassays to decentration of borate buffer at pH 8.0 is 0.18 M. The tect amphetamine or methamphetamine, the improvesample is treated with a small amount of dichromate to 20 ment which comprises: treating the sample to be asdestroy any ascorbic acid and 20 pl of sample is added sayed with aqueous periodate solution at a concentrato 5 ,ul of antibody solution and 5 ul of the spin label tion in the range of about 10 to 10 moles/ml in the at the appropriate buffer concentration. The sample is presence f a a niu h droxide in an amount sufthen taken up in an ESR capillary tube and read in an fici nt to provide a pH in the range of about 8 to 9. ESR spectrometer and the amphetamine concentration 6. A method according to claim 5, wherein said amdetermined by comparison with a standard. monium hydroxide is tetramethyl ammonium hydrox- The following table indicates the results. ide,
TABLE I1 FRAT* EM1T* pg/ml GLC Result pug/m1 ug/ml Without 10, With 10 Ampheta- Methamphemine 1 33111116 Total of amphetamine and methamphetamine The above results show that the periodate does not 7 A h d according to claim 5, wherein said amaffect the results obtained with amphetamine. Theremonium hydroxide is NH OH. fore, the amphetamine can be accurately assayed for by 50 8. A method according to claim 5, wherein said treatremoving interferants such as phenylpropanolamine ing is carried out at a temperature in the range of about without affecting the assay for the B-phenethylamine 10 to 40 C and for a time in the range of about 1 to derivative. 10 minutes.
Although the foregoing invention has been described 9. An aqueous solution which is 0.05 to 0.5 M in periin some detail by way of illustration and example for O e nd 0-5 to M m tetraalkylammonium hydroxide purposes of clarity of understanding, it will be obvious of from four to eight carbon atoms. that ertain hanges and modifications may be prac- 10- A SOiUtlQn according [O 9, wherein Silld tetticed within the scope of the invention, as limited only raalkylammomun? hydrfnlde tetralmethylammon"1m b h Scope f h d d l i hydroxide and said periodate ranges from 0.05 to 0.3
What is claimed is: 1. In an assay method for determining aralkyl amines,
M in concentration.

Claims (10)

1. IN AN ASSAY METHOD FOR DETERMINING ARALKYL AMINES, WHEREIN 1-ARALKYL B-HYDROXYAMINES INTERFERE, THE IMPROVEMENT WHICH COMPRISES: TREATING THE SAMPLE TO BE ASSAYED AT A PH GREATER THAN ABOUT 8 WITH AN AMOUNT OF AQUEOUS PERIODATE SOLUTION SUFFICIENT TO REMOVE THE HYDROXYAMINE INTERFERANT WHEREIN SAID PH IS MAINTAINED BY THE PRESENCE OF AN AMMONIUM HYDROXIDE.
2. A method according to claim 1, wherein the concentration of said periodate is in the range of about 10 3 to 10 7 moles/ml.
3. A method according to claim 1, wherein said periodate is at a concentration in the range of about 10 4 to 10 6 moles/ml.
4. A method according to claim 1, wherein the concentration of said ammonium hydroxide is in an amount of from 2 to 20 times the concentration of periodate and said ammonium hydroxide is tetraalkyl ammonium hydroxide.
5. In a method for carrying out immunoassays to detect amphetamine or methamphetamine, the improvement which comprises: treating the sample to be assayed with aqueous periodate solution at a concentration in the range of about 10 4 to 10 6 moles/ml in the presence of an ammonium hydroxide in an amount sufficient to provide a pH in the range of about 8 to 9.
6. A method according to claim 5, wherein said ammonium hydroxide is tetramethyl ammonium hydroxide.
7. A method according to claim 5, wherein said ammonium hydroxide is NH4OH.
8. A method according to claim 5, wherein said treating is carried out at a temperature in the range of about 10* to 40* C and for a time in the range of about 1 to 10 minutes.
9. An aqueous solution which is 0.05 to 0.5 M in periodate and 0.5 to 2 M in tetraalkylammonium hydroxide of from four to eight carbon atoms.
10. A solution according to claim 9, wherein said tetraalkylammonium hydroxide is tetramethylammonium hydroxide and said periodate ranges from 0.05 to 0.3 M in concentration.
US00320374A 1973-01-02 1973-01-02 Interferant removal from amphetamine immunoassay Expired - Lifetime US3856469A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00320374A US3856469A (en) 1973-01-02 1973-01-02 Interferant removal from amphetamine immunoassay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00320374A US3856469A (en) 1973-01-02 1973-01-02 Interferant removal from amphetamine immunoassay

Publications (1)

Publication Number Publication Date
US3856469A true US3856469A (en) 1974-12-24

Family

ID=23246127

Family Applications (1)

Application Number Title Priority Date Filing Date
US00320374A Expired - Lifetime US3856469A (en) 1973-01-02 1973-01-02 Interferant removal from amphetamine immunoassay

Country Status (1)

Country Link
US (1) US3856469A (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996344A (en) * 1972-05-15 1976-12-07 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies and use
US4378428A (en) * 1981-03-30 1983-03-29 Baker Instruments Corporation Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
US4444880A (en) * 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
US4785080A (en) * 1981-03-30 1988-11-15 Baker Instruments Corporation Labeled analytes
US4868132A (en) * 1987-02-03 1989-09-19 Abbott Laboratories Fluorescence polarization immunoassay for amphetamine/methamphetamine
US4952336A (en) * 1987-02-03 1990-08-28 Abbott Laboratories Fluorescence polymerization immunoassay for amphetamine/methamphetamine
US5101015A (en) * 1989-04-10 1992-03-31 Abbott Laboratories Reagents for an amphetamine-class fluorescence polarization immunoassay
US5248791A (en) * 1989-04-10 1993-09-28 Abbott Laboratories Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
US5260441A (en) * 1986-07-14 1993-11-09 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5262333A (en) * 1988-10-28 1993-11-16 Abbott Laboratories Method and reagents for detecting amphetamine and/or D-methamphetamine in biological samples
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5573955A (en) * 1995-06-05 1996-11-12 Microgenics Corp. Reducing tyramine interference in immunoassays for amphetamine and methamphetamine
US5652146A (en) * 1993-11-02 1997-07-29 Private Clinic Laboratories, Inc. Method of monitoring patient compliance with medications prescriptions
US5776783A (en) * 1993-11-02 1998-07-07 Private Clinic Laboratories, Inc. Method of monitoring therapeutic agent consumption
WO1999002983A1 (en) * 1997-07-07 1999-01-21 U. D. Testing, Inc. Urine adulteration test method
US6124136A (en) * 1993-11-02 2000-09-26 U. D. Testing, Inc. Method of monitoring compliance with methadone treatment program
US6136801A (en) * 1998-12-24 2000-10-24 U. D. Testing, Inc. Therapeutic agent with quantitative consumption marker
US6174688B1 (en) * 1998-03-13 2001-01-16 The United States Of America As Represented By The Secretary Of The Navy Multiassay method for determining the concentrations of antigens and interferants
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
US6589779B1 (en) 1999-07-16 2003-07-08 Board Of Regents, The University Of Texas System General signaling protocol for chemical receptors in immobilized matrices
US20030186228A1 (en) * 2000-01-31 2003-10-02 Mcdevitt John T. Portable sensor array system
US20040029259A1 (en) * 2002-04-26 2004-02-12 Mcdevitt John T. Method and system for the detection of cardiac risk factors
US6867002B2 (en) * 1998-10-20 2005-03-15 Matsushita Electric Industrial Co., Ltd. Sample treating kit and sample treating method using the same for analysis with a biosensor
US6908770B1 (en) 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
EP1354186A4 (en) * 2001-01-23 2005-07-27 Varian Inc Lateral flow testing device with on-board chemical reactant
US7022517B1 (en) 1999-07-16 2006-04-04 Board Of Regents, The University Of Texas System Method and apparatus for the delivery of samples to a chemical sensor array
US20060228256A1 (en) * 2003-02-07 2006-10-12 Board Of Regents, The University Of Texas System Multi-shell microspheres with integrated chomatographic and detection layers for use in array sensors
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
US8105849B2 (en) 2004-02-27 2012-01-31 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
JP2021531448A (en) * 2018-07-10 2021-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Methods for Reducing Drug Target Interference in Anti-Drug Antibody (ADA) Immune Assays

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, 63: 8942f, (1965). *
L. Chafetz, J. Pharm. Sci., 52, (12), 1193 1195, (1963). *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996344A (en) * 1972-05-15 1976-12-07 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies and use
US4378428A (en) * 1981-03-30 1983-03-29 Baker Instruments Corporation Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
US4785080A (en) * 1981-03-30 1988-11-15 Baker Instruments Corporation Labeled analytes
US4444880A (en) * 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
US5260441A (en) * 1986-07-14 1993-11-09 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US4868132A (en) * 1987-02-03 1989-09-19 Abbott Laboratories Fluorescence polarization immunoassay for amphetamine/methamphetamine
US4952336A (en) * 1987-02-03 1990-08-28 Abbott Laboratories Fluorescence polymerization immunoassay for amphetamine/methamphetamine
EP0279213B1 (en) * 1987-02-03 1992-10-21 Abbott Laboratories Fluorescence polarization immunoassay for amphetamine/methamphetamine
US5262333A (en) * 1988-10-28 1993-11-16 Abbott Laboratories Method and reagents for detecting amphetamine and/or D-methamphetamine in biological samples
US5101015A (en) * 1989-04-10 1992-03-31 Abbott Laboratories Reagents for an amphetamine-class fluorescence polarization immunoassay
US5248791A (en) * 1989-04-10 1993-09-28 Abbott Laboratories Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
US5354693A (en) * 1989-04-10 1994-10-11 Abbott Laboratories Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassy
US6124136A (en) * 1993-11-02 2000-09-26 U. D. Testing, Inc. Method of monitoring compliance with methadone treatment program
US5955370A (en) * 1993-11-02 1999-09-21 U.D. Testing, Inc. Urine adulteration test method
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5652146A (en) * 1993-11-02 1997-07-29 Private Clinic Laboratories, Inc. Method of monitoring patient compliance with medications prescriptions
US5776783A (en) * 1993-11-02 1998-07-07 Private Clinic Laboratories, Inc. Method of monitoring therapeutic agent consumption
US5908788A (en) * 1993-11-02 1999-06-01 U.D. Testing, Inc. Method of monitoring patient compliance with medications prescriptions
WO1996039492A1 (en) * 1995-06-05 1996-12-12 Boehringer Mannheim Corporation Reducing tyramine interference in (met)amphetamine immunoassays
US5573955A (en) * 1995-06-05 1996-11-12 Microgenics Corp. Reducing tyramine interference in immunoassays for amphetamine and methamphetamine
WO1999002983A1 (en) * 1997-07-07 1999-01-21 U. D. Testing, Inc. Urine adulteration test method
US6174688B1 (en) * 1998-03-13 2001-01-16 The United States Of America As Represented By The Secretary Of The Navy Multiassay method for determining the concentrations of antigens and interferants
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
US7491552B2 (en) 1998-07-16 2009-02-17 The Board Of Regents Of The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6908770B1 (en) 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6867002B2 (en) * 1998-10-20 2005-03-15 Matsushita Electric Industrial Co., Ltd. Sample treating kit and sample treating method using the same for analysis with a biosensor
US6136801A (en) * 1998-12-24 2000-10-24 U. D. Testing, Inc. Therapeutic agent with quantitative consumption marker
US6602702B1 (en) 1999-07-16 2003-08-05 The University Of Texas System Detection system based on an analyte reactive particle
US7022517B1 (en) 1999-07-16 2006-04-04 Board Of Regents, The University Of Texas System Method and apparatus for the delivery of samples to a chemical sensor array
US6589779B1 (en) 1999-07-16 2003-07-08 Board Of Regents, The University Of Texas System General signaling protocol for chemical receptors in immobilized matrices
US6649403B1 (en) 2000-01-31 2003-11-18 Board Of Regents, The University Of Texas Systems Method of preparing a sensor array
US6713298B2 (en) 2000-01-31 2004-03-30 Board Of Regents, The University Of Texas System Method and apparatus for the delivery of samples to a chemical sensor array
US7316899B2 (en) 2000-01-31 2008-01-08 The Board Of Regents Of The University Of Texas System Portable sensor array system
US20030186228A1 (en) * 2000-01-31 2003-10-02 Mcdevitt John T. Portable sensor array system
EP1354186A4 (en) * 2001-01-23 2005-07-27 Varian Inc Lateral flow testing device with on-board chemical reactant
US20040029259A1 (en) * 2002-04-26 2004-02-12 Mcdevitt John T. Method and system for the detection of cardiac risk factors
US8257967B2 (en) 2002-04-26 2012-09-04 Board Of Regents, The University Of Texas System Method and system for the detection of cardiac risk factors
US20060228256A1 (en) * 2003-02-07 2006-10-12 Board Of Regents, The University Of Texas System Multi-shell microspheres with integrated chomatographic and detection layers for use in array sensors
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
US8105849B2 (en) 2004-02-27 2012-01-31 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
JP2021531448A (en) * 2018-07-10 2021-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Methods for Reducing Drug Target Interference in Anti-Drug Antibody (ADA) Immune Assays
US12055551B2 (en) 2018-07-10 2024-08-06 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay

Similar Documents

Publication Publication Date Title
US3856469A (en) Interferant removal from amphetamine immunoassay
CA1225586A (en) Method of performing an immuno-assay, article for use therein and method for making such article
US4241176A (en) Magnetic gel suitable to immunoenzymatic determinations
SU1554782A3 (en) Method of determining antigens or antibodies
US5358851A (en) Immunoassay for aromatic ring containing compounds
US4435509A (en) Assays, including immunoassays with FITC label activated by sodium hypochlorite
GB1603001A (en) Determination of immunogens and antibodies
CA1146067A (en) Solid phase immunoassay with labelled anti-hapten antibody
US3658982A (en) Stable latex reagent for the detection of rheumatoid arthritis
US4163779A (en) Test for quantitation of immunoglobulin and identification of abnormal immunoglobulin
Schroeder et al. Immunochemiluminometric assay for hepatitis B surface antigen.
US4299812A (en) Immunoassay of thyroxine in neonates using dried blood samples
JPS604938B2 (en) Immunological reagents and their use
WO2007081868A9 (en) Determination of concentration of fk778 by competitive immunoassay
Sakai et al. Selective and repeatable detection of human serum albumin by using piezoelectric immunosensor
CN118033148B (en) Fluorescent immunochromatography test strip for detecting anti-MDA 5 antibody
WO1990015328A1 (en) Improved immunoassay
CN108802367A (en) A kind of chemical luminescence ELISA detection kit of vancomycin
KR20010025027A (en) Immunoassay reagents and immunoassay method
ATE138203T1 (en) TESTING METHODS FOR ANTIGENS OR ANTIBODIES
JPS61250558A (en) immunoassay method
Elliott et al. Development of a dual label time‐resolved fluoroimmunoassay for the detection of (β‐agonists in cattle urine
EP0253270B1 (en) Method for diagnostic immunoassay by solid phase separation
Mathews et al. Microvolume, kinetic-dependent enzyme-linked immunosorbent assay for amoeba antibodies
Tsay et al. Quantitation of serum gentamicin concentration by a solid-phase immunofluorescence method.

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEUTSCHE BANK AG, NEW YORK

Free format text: ;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013516/0250

Effective date: 20021001

Owner name: DEUTSCHE BANK AG, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013599/0629

Effective date: 20021003

AS Assignment

Owner name: DEUTSCHE BANK AG, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:SYVA COMPANY;REEL/FRAME:013542/0411

Effective date: 20021001

AS Assignment

Owner name: DADE MICROSCAN INC., ILLINOIS

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0315

Effective date: 20050426

Owner name: SYVA COMPANY, ILLINOIS

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0326

Effective date: 20050426